- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Experimental Treatment for Diabetic Kidney Disease Based on Precision Medicine
The drug, baricitinib, is a JAK-STAT inhibitor being developed for rheumatoid arthritis. Research by scientists at the Unviersity of Michigan found a key role for the pathway in diabetic patients suffering from kidney disease.
Phase 2 trial results presented at the recently concluded annual meeting of the American Diabetes Association (ADA) narrate a story of how a successful partnership between academia and the pharmaceutical industry has resulted in what could be a precision treatment for diabetic kidney disease.
Scientists at the University of Michigan studying the disease condition identified an overactive JAK/STAT signaling pathway in many kidney cells damaged by hyperglycemia. The JAK/STAT pathway is also activated in individuals suffering from the inflammatory disease of the immune system, rheumatoid arthritis (RA). Scientists at Eli Lilly & Co who were developing baricitinib to inhibit the JAK/STAT pathway in RA, approached the University of Michigan team to test the drug in their kidney disease model. In just over a year, a phase 1 clinical trial was initiated to test the drug in 129 adult patients.
Results presented at ADA from the phase 2 studies showed that the drug reduced a key sign of kidney damage, with few side effects, and it had a sustained impact even after patients stopped taking it.
Read more on ScienceDaily: http://bit.ly/1B5i7dO
Contributor: More Informed Management of Preeclampsia Is Necessary
November 29th 2023At present, it is difficult for clinicians to identify patients at greatest risk for developing preeclampsia with severe features and tailor treatment plans for them; this difficulty increases costs significantly.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
Provisional CDC data show that US babies gained roughly a year in life expectancy in 2022; study findings indicate that the COVID-19 pandemic significantly raised the risk of preterm birth for expectant California mothers; New York Attorney General Letitia James said about 4 million New Yorkers were affected by a data breach of the medical transcription company Perry Johnson & Associates.
Read More
A Look at Racial Disparities in US HPV Vaccine Uptake
March 1st 2022On this episode of Managed Care Cast, Leslie Cofie, PhD, MPH, an assistant professor of health education and promotion at the College of Health and Human Performance, East Carolina University, discusses his work on identifying and addressing racial disparities in human papillomavirus (HPV) vaccine uptake in the United States.
Listen
Gene Therapy Success in UK Likely Depends on Overcoming Education, Psychological Support Challenges
November 27th 2023Education, psychological support, and implementation guidance are the top unmet needs identified by investigators from the United Kingdom concerning gene therapy use for hemophilia.
Read More
